DUBLIN--(BUSINESS WIRE)--The "Active Pharmaceutical Ingredients Market by Manufacturing Type and Geography - Forecast and Analysis 2020-2024" report has been added to ResearchAndMarkets.com's offering.
Global Active Pharmaceutical Ingredients Market: About this market
The active pharmaceutical ingredients market analysis considers sales from captive API and contract API. Our study also finds the sales of active pharmaceutical ingredients in Asia, Europe, North America, and ROW. In 2019, the contract API segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing demand for low-cost drugs will play a significant role in the contract API segment to maintain its market position. Also, our global active pharmaceutical ingredients market report looks at factors such as evolving API manufacturing scenarios in developing countries, increasing the number of type II drug master (DMFs), and growing need to focus on core competencies. However, growing concerns regarding outsourced APIs and capacity utilization constraints may hamper the growth of the active pharmaceutical ingredients industry over the forecast period.
Global Active Pharmaceutical Ingredients Market: Overview
Increasing number of type II drug master files (DMFs)
The market has witnessed a steady rise in the number of DMF filings over the past two decades. This is due to the increasing investments to enhance manufacturing facilities by Asian companies to meet international quality standards. In addition, market players in India are increasingly focusing on achieving compliance with standards laid by various regulatory agencies such as the US FDA, TGA, MHRA, Brazilian Health Regulatory Agency, and SAHPRA. The increasing DMF approvals by regulatory agencies are providing significant growth opportunities for API manufacturers. Such factors will lead to the expansion of the global active pharmaceutical ingredients market at a CAGR of over 6% during the forecast period.
Paradigm shift in API manufacturing
Traditionally, most of the pharmaceutical companies have been relying on their in-house capabilities for the discovery, development, and manufacturing of APIs. However, the captive API manufacturing has seen an overhaul in the last few decades as many pharmaceutical companies are focusing on outsourcing a large share of their research and manufacturing processes to CMOs or other drug manufacturing organizations. The decision to outsource an API depends on several factors, such as industry trends, the cost of acquiring new in-house technologies, and the availability of internal capacity. Outsourcing of API enables innovators as well as generic drug manufacturers to meet aggressive development timelines while capitalizing significant efficiencies in the supply chain. This development is expected to have a positive impact on the overall market growth.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Value chain analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2019
- Market size and forecast 2019-2024
- Market outlook
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: MARKET SEGMENTATION BY MANUFACTURING TYPE
- Market segmentation by manufacturing type
- Comparison by manufacturing type
- Captive API - Market size and forecast 2019-2024
- Contract API - Market size and forecast 2019-2024
- Market opportunity by manufacturing type
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Asia - Market size and forecast 2019-2024
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Increasing geriatric population
- Paradigm shift in API manufacturing
- Increasing patent expiries
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amneal Pharmaceuticals Inc.
- Cadila Healthcare Ltd.
- Jazz Pharmaceuticals Plc
- Lupin Ltd.
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/hne4nh
